Abeona Therapeutics (ABEO)

Executive Summary

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for rare diseases. The company's lead program, EB-101, is a gene-corrected autologous epidermal sheet for recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disorder. EB-101 has completed a pivotal Phase 3 trial, with top-line data showing statistically significant wound healing benefits. The company also has a commercial product, ZEVASKYN, and a proprietary AIM vector platform for gene therapy delivery. With a strong balance sheet and a clear regulatory path, Abeona is poised to address significant unmet needs in rare disease.

Upcoming Catalysts (preview)

• Q3 2026BLA submission for EB-101 in RDEB80% success
• Q4 2026Regulatory update on manufacturing capacity for EB-10170% success
• 2027Partnership or licensing deal for AIM vector platform50% success